Inactive Instrument

Bioadaptives Inc Stock OTC Bulletin Board

Equities

US09072U1079

Food Processing

Sales 2022 0.02 Sales 2023 0.03 Capitalization 448K
Net income 2022 - Net income 2023 - EV / Sales 2022 30,165,231 x
Net Debt 2022 367K Net Debt 2023 268K EV / Sales 2023 25,075,337 x
P/E ratio 2022
-0.07 x
P/E ratio 2023
-0.39 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 78.65%
More Fundamentals * Assessed data
Dynamic Chart
BioAdaptives, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Bioadaptives, Inc. Announces Naturacomplete?, an All-In-One Supplement to Optimize Its Ai-Based FYO Obesity Management System CI
BioAdaptives Announces Signing of a New Distributor?s Agreement for AI Body Composition Measuring App and New Weight Management System CI
BioAdaptives Inc. Announces the Development of PROTEINnMORETM CI
BioAdaptives Announces the Development of VeganHepPlusTM Liver Supplement Formula CI
BioAdaptives, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BioAdaptives, Inc. Highlights Continued Success of Popular LUNG ARMOR System as US Enters Flu Season CI
BioAdaptives, Inc. Announces Nationwide Launch of Lung Fortress Natural Supplement CI
BioAdaptives, Inc. Commences Development of A New Supplement for Women?S Health CI
BioAdaptives, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
BioAdaptives, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
BioAdaptives, Inc. Announces the Appointment of David Allen to its Board of Directors CI
BioAdaptives, Inc. Signs Non-Exclusive Marketing Agreement with World Wellness, LLC CI
BioAdaptives, Inc. Announces the Appointment of Dr. Yaguang Liu to its Board of Directors CI
BioAdaptives, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 83 18-03-14
Director of Finance/CFO 82 19-09-10
Chief Operating Officer 78 21-05-30
Members of the board TitleAgeSince
Chief Executive Officer 83 18-03-14
Director of Finance/CFO 82 19-09-10
Chief Operating Officer 78 21-05-30
More insiders
BioAdaptives, Inc. investigates, markets, and distributes natural plant- and algal-based products that enhance health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. Its product line for humans includes PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven, and ProteinNMore. The Company also markets the Lung Flute and PrimiLungs products in its Lung Armor packaging, emphasizing the anti-viral properties of the nutraceutical and general respiratory health benefits from use of the device. Its animal products include Canine All-in-One and Equine All-in-One products for dogs and horses. Pluripain is a fast-acting, long-lasting all-natural pain relief formulation. MindnMemory is a nootropic formulation that enhances memory, focus, mental clarity and endurance.
More about the company